Detalhe da pesquisa
1.
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med
; 389(21): 1961-1971, 2023 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870920
2.
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Lancet
; 402(10398): 291-303, 2023 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37285865
3.
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
N Engl J Med
; 384(12): 1125-1135, 2021 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33577729
4.
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer.
Future Oncol
; 20(9): 493-505, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37882449
5.
Baseline characteristics may impact treatment duration of cabazitaxel in patients with mCRPC: a subanalysis of data from a post-marketing surveillance.
Jpn J Clin Oncol
; 54(1): 97-102, 2024 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37807695
6.
Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.
Cancer Sci
; 114(2): 574-585, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35838190
7.
First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part.
Cancer
; 129(15): 2348-2359, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37080942
8.
Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan.
BMC Cancer
; 23(1): 538, 2023 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37308888
9.
Clinical features of CDK4/6 inhibitor-related interstitial lung disease in patients with breast cancer: a case series study.
Jpn J Clin Oncol
; 53(2): 105-114, 2023 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36373891
10.
Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study.
Int J Clin Oncol
; 28(2): 289-298, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36534263
11.
Comprehensive investigation of clinicopathological and immunological features to determine prognostic impact in metastatic renal cell carcinoma: The JEWEL study.
Int J Urol
; 30(11): 977-984, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37434386
12.
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(3): 393-405, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35157830
13.
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 398(10295): 131-142, 2021 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34246347
14.
Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer.
BMC Cancer
; 22(1): 470, 2022 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35484517
15.
IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation.
BMC Cancer
; 22(1): 1292, 2022 Dec 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36494792
16.
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
Br J Clin Pharmacol
; 88(7): 3182-3192, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35029306
17.
Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis.
Jpn J Clin Oncol
; 52(5): 441-448, 2022 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35229141
18.
Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
Int J Clin Oncol
; 27(1): 154-164, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34800178
19.
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(7): 931-945, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34051178
20.
Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies.
Cancer Sci
; 112(2): 725-733, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33031626